![[ARTICLE] Diet supplementation with the probiotic Saccharomyces cerevisiae helps alleviate abdominal pain of IBS patients.](https://www.biofortis.fr/wp-content/uploads/2022/06/Post_website_article_Saccharomyces-1080x675.png)
by Administrateur Biofortis | Jun 28, 2022 | Microbiome
IBS is a 3-letter acronym that strongly impacts the lives of millions of people worldwide. It stands for irritable bowel syndrome, a complex condition that exhibits various forms, depending on the predominant stool pattern: diarrhea, constipation, mixed or...
![[EVENT] Global Engage Microbiome & Probiotic R&D & Business Collaboration Forum: Europe](https://www.biofortis.fr/wp-content/uploads/2022/05/Post-SM-GLOBAL-ENGAGE.png)
by Administrateur Biofortis | May 17, 2022 | News
May 24th and 25th, 2022 We are pleased to meet you again during Global Engage – May 24th/25th in the Netherlands. Our team will remain at your disposal to discuss with you about Microbiome Projects at our booth. Don’t forget to stop by the poster session, we...
by Administrateur Biofortis | Apr 19, 2022 | Microbiome
After a long Easter weekend filled with chocolate, it’s time to offer you an infographic on the impact of chocolate on the human microbiome. A digest of different articles on cocoa is the best way to understand the link between chocolate and microbiome, you will find...
![[EVENT] Biofortis will be present at Outsourcing In Clinical Trials Europe 2022](https://www.biofortis.fr/wp-content/uploads/2022/04/Post-SM-OCT.png)
by Administrateur Biofortis | Apr 14, 2022 | News
May 4th and 5th 2022 Come and meet us at the Outsourcing In Clinical Trials (OCT) Europe 2022 in Barcelona, Spain. This event will provide participants with practical take-away messages and solutions to their most encountered operational and outsourcing challenges in...
![[EVENT] – Biofortis will be present at PHARMABIOTICS 2022](https://www.biofortis.fr/wp-content/uploads/2022/04/Post-SM_PHARMABIOTICS.jpg)
by Administrateur Biofortis | Apr 5, 2022 | News
For this 2022 edition, Biofortis will be present during the Pharmabiotic Research Institute (PRI)’s annual conference in Lyon, France, 20/21 April 2022. Our CSO, Françoise Le Vacon will lead a session during the second day : “First in Human Clinical Trials”...
